Global progress against cancer—challenges and opportunities

References

1. 1.↵
   2. Ferlay J,
   3. Shin HR,
   4. Bray F,
   5. Forman D,
   6. Mathers C,
   7. Parkin DM

   . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–2917.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   2. Bray F,
   3. Jemal A,
   4. Grey N,
   5. Ferlay J,
   6. Forman D

   . Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012;13:790–801.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   2. Hanahan D,
   3. Weinberg RA

   . The hallmarks of cancer. Cell 2000;100:57–70.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   2. Hanahan D,
   3. Weinberg RA

   . Hallmarks of cancer: the next generation. Cell 2011;144:646–674.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   2. Vogelstein B,
   3. Papadopoulos N,
   4. Velculescu VE,
   5. Zhou S,
   6. Diaz LA,
   7. Kinzler KW

   . Cancer genome landscapes. Science 2013;339:1546–1558.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   2. Garraway LA,
   3. Lander ES

   . Lessons from the cancer genome. Cell 2013;153:17–37.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   2. Socinski MA,
   3. Bondarenko I,
   4. Karaseva NA,
   5. Makhson AM,
   6. Vynnychenko I,
   7. Okamoto I, et al.

   Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30:2055–2062.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2. Von Hoff DD,
   3. Ervin TJ,
   4. Arena FP,
   5. Chiorean EG,
   6. Infante JR,
   7. Moore MJ, et al.

   Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol 2013;31:abstr 4005.
9. 9.↵
   2. Tan J,
   3. Cang S,
   4. Ma Y,
   5. Petrillo RL,
   6. Liu D

   . Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Juergens RA,
    3. Wrangle J,
    4. Vendetti FP,
    5. Murphy SC,
    6. Zhao M,
    7. Coleman B, et al.

    Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598–607.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    2. Topalian SL,
    3. Weiner GJ,
    4. Pardoll DM

    . Cancer immunotherapy comes of age. J Clin Oncol 2011;29:4828–4836.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    American Cancer Society. The global economic cost of cancer. Atlanta, GA: American Cancer Society, 2010.